Document is current
Any future updates will be listed below
-
Authors
Grunenberg, Alexander https://orcid.org/0000-0003-1632-917X
Kaiser, Lisa M.
Woelfle, Stephanie
Schmelzle, Birgit
Viardot, Andreas
Möller, Peter
Barth, Thomas F. E.
Muche, Rainer
Dreyhaupt, Jens
Raderer, Markus
Kiesewetter, Barbara
Buske, Christian
-
Funding
Funding for this research was provided by:
Universitätsklinikum Ulm
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 9 June 2021
First Online: 29 June 2021
Declarations
:
: The ethics committee of Ulm University approved the COUP-1 trial as leading ethics committee for all German sites. In addition, the leading Austrian ethics committee also approved the study. All patients signed informed consent according to GCP.The trial is registered at (NCT03474744) and the European Clinical Trials Database (2017 EudraCT: 2017–003150-16). Protocol version: 4.0. (May 5th 2020).
: Not applicable.
: Copanlisib and Rituximab are provided by Bayer AG and Celltrion Healthcare. The authors declare no conflicts of interest. The study was not externally reviewed. The authors have no financial relationship with Bayer AG or Celltrion Healthcare.
